Event‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
High‐dose chemotherapy followed by autologous haematopoietic cell… showed no clear difference in event‐free survival (reported as number of participants with… compared with conventional chemotherapy plus whole lung irradiation (low certainty).
1 finding from 1 review
Overall survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality‐adjusted survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Toxicity · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · children, adolescents, and young adults with primary metastatic Ewing sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
30‐Day mortality · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Vessel patency (at end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Duration of thrombolysis (to end of treatment) · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Stroke · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Major bleeding · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
30‐Day amputation‐free survival · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Amputation · patients with < 42 days' limb ischaemiaa
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose showed no clear difference in participant global assessment of treatment success: proportion with… compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
High‐dose may leads to higher total adverse events compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · adults and children with hemophilia A or B with inhibitors
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found